PMFER – Pemetrexed for Injection 100 mg / 500 mg
Product Overview
PMFER (Pemetrexed for Injection 100 mg / 500 mg) is a sterile lyophilized powder containing Pemetrexed, an antifolate antineoplastic agent indicated for the treatment of non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. It is administered as an intravenous infusion under the supervision of qualified oncology professionals.
Pemetrexed inhibits multiple folate-dependent enzymes involved in DNA and RNA synthesis, thereby preventing the growth and multiplication of rapidly dividing cancer cells. PMFER is commonly used as monotherapy or in combination with platinum-based chemotherapy according to established oncology treatment protocols.
| Attribute | Details |
|---|---|
| Brand Name | PMFER |
| Generic Name | Pemetrexed for Injection |
| Available Strengths | 100 mg / 500 mg |
| Dosage Form | Lyophilized Powder for Solution for Infusion |
| Packaging | Single-Dose Vial |
| Therapeutic Category | Anticancer / Antifolate Agent |
| Route of Administration | Intravenous (IV) Infusion |
| Prescription Status | Prescription Medicine |
| Manufacturer | Pharmafer Pvt. Ltd. |
| Storage | Store below 30°C. Protect from light and moisture. |
Uses of PMFER
PMFER is indicated for:
- Malignant pleural mesothelioma
- Locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
- Maintenance treatment of eligible NSCLC patients following platinum-based chemotherapy
- Second-line treatment of advanced NSCLC as determined by the treating oncologist
- Combination chemotherapy with cisplatin according to approved treatment protocols
Benefits
Proven Antifolate Chemotherapy
Contains Pemetrexed, a well-established antifolate agent used in the treatment of non-squamous NSCLC and malignant pleural mesothelioma.
Multiple Clinical Applications
Can be used as first-line combination therapy, maintenance therapy, or second-line treatment depending on the patient’s condition and treatment plan.
Targeted Inhibition of Cell Growth
Interferes with folate-dependent enzymes required for DNA and RNA synthesis, helping inhibit cancer cell proliferation.
Flexible Strength Options
Available in 100 mg and 500 mg single-dose vials to support individualized dosing based on body surface area and clinical protocol.
Hospital-Based Oncology Care
Designed for administration by trained healthcare professionals in specialized oncology settings.
Possible Side Effects
Like all chemotherapy medicines, PMFER may cause side effects, although not every patient experiences them.
Common side effects include:
- Fatigue
- Nausea and vomiting
- Loss of appetite
- Anemia
- Low white blood cell count (neutropenia)
- Low platelet count (thrombocytopenia)
- Mouth sores (stomatitis)
- Skin rash
- Diarrhea
- Increased risk of infections
Patients should seek immediate medical attention if they experience fever, unusual bleeding, severe skin reactions, or persistent breathing difficulties.
Mechanism of Action
Pemetrexed is a multitargeted antifolate that inhibits several folate-dependent enzymes involved in the synthesis of purines and pyrimidines, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). This inhibition disrupts DNA and RNA synthesis, preventing cancer cell growth and division.
Dosage & Administration
PMFER should be administered only under the supervision of a qualified oncologist or trained healthcare professional. It is supplied as a lyophilized powder that must be reconstituted and diluted prior to intravenous infusion. The dosage is determined according to the patient’s body surface area, diagnosis, renal function, and chemotherapy protocol. Patients receiving PMFER are generally prescribed folic acid, vitamin B12 supplementation, and corticosteroids to help reduce treatment-related toxicity. Regular clinical and laboratory monitoring is recommended throughout therapy.
Frequently Asked Questions
PMFER is used in the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer as prescribed by an oncologist.
PMFER contains Pemetrexed, which blocks enzymes required for DNA and RNA synthesis, helping stop the growth and multiplication of cancer cells.
PMFER is administered as an intravenous infusion by qualified healthcare professionals in a hospital or oncology center.
These supplements are commonly prescribed to help reduce certain treatment-related side effects while maintaining the effectiveness of therapy.
Yes. Blood counts, kidney function, liver function, and overall clinical response are routinely monitored throughout treatment.
